ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09 trial. In the phase III study after a median of follow-up of 29 months, patients randomized to T-DXd plus pertuzumab had a median PFS by blinded independent central review […]